CDKN2A and neoplasm: We observed various responses to palbociclib concerning both models (CD3, CD7) harboring a loss of CDKN2A/2B, and no tumor efficacy in the non-CDKN2A/2B-deleted PBRM1-mutated PDX (CD39).